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ABSTRACT 
Objective: To develop and validate stability indicating RP-HPLC gradient method for simultaneous estimation of impurities and degradation 
products from Olmesartan Medoximil and Hydrochlorothiazide tablet. 
Methods: The chromatographic separation was achieved by using Inertsil ODS (250 mm x 4.6 mm, 5μ) column. The mobile phase-A consists of 
0.01M potassium dihydrogen phosphate buffer pH 3.2 adjusted using orthophosphoric acids and acetonitrile as mobile phase-B. The flow rate was 1 
ml/min, and chromatograms extracted at wavelength 225 nm.  
Results: The method was found linear from LOQ to 0.4% level with respect to target concentrations of Olmesartan Medoximil (1.6 mg/ml) and 
Hydrochlorothiazide (0.5 m/ml) for all impurities, with correlation coefficient found greater than 0.99. The method found robust in all deliberate 
variations of method parameters as a resolution between adjacent peaks found greater than 2.0. The % RSD results for precision and intermediate 
precision found less than 5.0%. 
Conclusion: The proposed analytical method was found to be robust, stability indicating and can be used for estimation of impurities and 
degradation products of Olmesartan Medoximil and Hydrochlorothiazide from tablet dosage form. 
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INTRODUCTION 
Olmesartan Medoximil chemically, it is 4-(1-Hydroxy-1-methylethyl) 
-2-propyl-1-((2'-(1H-tetazol-5-yl) (1, 1'-biphenyl)-4-yl) methyl)-1H-
imidazole-5-carboxylic acid (5-Methyl-2-oxo-1, 3-dioxol-4-yl) 
methyl ester. It works by blocking a substance in the body that 
causes blood vessels to tighten. As a result, Olmesartan relaxes blood 
vessels. This lowers blood pressure and increases the supply of 
blood and oxygen to the heart. Olmesartan prevents the constriction 
of blood vessels (1). Olmesartan is a non-peptide molecule. 
Hydrochlorothiazide chemically, it is 6-Chloro-3, 4-dihydro-2H-1, 2, 
4-benzothiadiazine-7-sulfonamide 1, 1-dioxide, reduces the amount 
of water in the body by increasing the flow of urine, which helps 
lower the blood pressure (2).  
The levels of impurity changes due to route of synthesis, reaction 
condition, sources and quality of starting material, reagents and 
solvents used during synthesis, the purification steps, and conditions 
of crystallization, drying, distillation and storage of bulk drug 
materials. The same things were applied to formulation too thereof 
have to check repeatedly on impurity profiling during the research 
and development as drug interact with various excipients. In order 
to ensure the quality and efficacy of drug product regulatory 
authorities such as US FDA, CGMP, TGA and MCA insist on the 
impurity profiling of drugs. 
Literature review reveals that the methods for Olmesartan 
Medoximil alone are developed and validated using Ultra violet-
visible Spectrophotometry and Reverse-Phase High-Performance 
Liquid Chromatography from Tablet dosage form (3, 4). Also, there 
are analytical methods available for determination of Olmesartan 
Medoximil and Hydrochlorothiazide from the biological matrix (5, 
8). Some of the methods have been reported for Olmesartan and 
Hydrochlorothiazide by HPLC (9, 13), LCMS (14, 15) and HPTLC 
(16). Most of available RP-LC methods were for estimation of 
Olmesartan Medoximil and Hydrochlorothiazide from a combination 
of the dosage form. There was no any official pharmacopoeial 
method for Simultaneous estimation of impurities and degradation 
products from Olmesartan Medoximil and Hydrochlorothiazide 
reported till date. The present analytical method was robust, 
economical and stability-indicating for estimation of impurities and 
degradation products from the combination of tablet dosage form. 
MATERIALS AND METHODS 
Instrumentation 
Waters HPLC system with photodiode array detector was used for 
method development and forced degradation studies. The HPLC 
system consists of 2695 separation module and 2998 photodiode 
array detector. The output signal was monitored and processed 
using Empower 2 software. Hydrolysis studies were performed in 
water bath (Make-Bio-analytical ltd) and thermal stability studies 
were performed in oven (Make-Bio-analytical ltd) 
Chemicals and reagents 
Active pharmaceutical ingredients are Olmesartan Medoximil and 
Hydrochlorothiazide and its related impurities obtained from 
veeprho laboratories pvt. Ltd. Marketed formulation of Olmesartan 
Medoximil and Hydrochlorothiazide obtained from Ajanta 
pharmaceuticals Ltd. Analytical grade potassium dihydrogen 
phosphate obtained from Merck (Mumbai India), HPLC grade 
Acetonitrile obtained from Merck (Darmstadt, Germany), water from 
milli-Q purification system (Millipore, Bedford, USA) and GR grade 
orthophosphoric acid obtained from (Merck, Mumbai). 
Chromatographic conditions 
The chromatographic separation was achieved by Inertsil C18, 250 
mm x 4.6 mm column. The mobile phase-A consists of 0.01M KH2PO4 
Buffer (pH 3.2) adjusted using diluted orthophosphoric acid and 
Acetonitrile as mobile phase-B. The flow rate was 1.0 ml/min 
throughout the gradient program. The eluents were monitored at 
225 nm. The column temperature was maintained at 30 °C. The 
injection volume was 10 µl. The diluent was prepared by mixing of 
buffer pH 3.2 and acetonitrile in the ratio of 1:1 (v/v). The gradient 
program was set as: time (min)/% mobile phase B: 0/10, 10/20, 
20/35, 35/50, 45/85, 55/85, 60/10 and 70/10. 
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Preparation of stock solutions 
A stock solution of Olmesartan Medoximil (1.60 mg/ml) and 
Hydrochlorothiazide (0.5 mg/ml) was prepared by dissolving an 
appropriate amount in the diluent. A stock solution of impurities 
(0.1 mg/ml) was prepared individually in the diluent. Working 
solutions were prepared from stock solutions respectively. 
Preparation of sample solutions 
Weigh and transferred powder equivalent to 25 mg of 
Hydrochlorothiazide into 50 ml volumetric flask added about 35 ml 
diluent and sonicated for 20 min with intermittent shaking. The 
solution was diluted to 50 ml with diluent and mix well keep the 
solution on the bench for 2 min and filtered above solution through 
0.45 µm Nylon syringe filter. 
RESULTS AND DISCUSSION 
Method development and optimization 
The main objective of the chromatographic method was to separate 
all impurities from each other and from Olmesartan Medoximil and 
Hydrochlorothiazide peaks. As isocratic method was not able to give 
adequate selectivity and rapid separation of impurities hence, the 
gradient method was developed. The stress conditions used for forced 
degradation includes acid hydrolysis (0.1N HCl at bench top for 1Hr), 
Base hydrolysis (0.01M NaoH at bench top for 30 min), Peroxide stress 
(10% H2O2 at bench top for 5 min), Humidity stress (40 °C/75% RH), 
Heat stress (80 °C for 24 Hr) and Photolytic stress. In stress conditions, 
Olmesartan medoximil acid impurity was major degradent. 
System suitability 
System suitability evaluated with the parameters such as tailing 
factor (should be<2.0), theoretical plate (should be>10,000) and 
%RSD for replicate injections of standard solution (should<5.0). The 
results for proposed method depicted in (table 1). In system 
suitability found the resolution for all adjacent peaks more than2.0, 
tailing factor less than 2.0, theoretical plates more than 10,000 and 
% RSD for six replicate injections of a diluted standard below 5.0%. 
Specificity and forced degradation 
All the degradation study samples were analyzed using a PDA 
detector with respective concentration of Olmesartan medoximil 
(1.6 mg/ml) and Hydrochlorothiazide (0.5 mg/ml). During stress 
study found that Olmesartan Medoximil labile to degradation in acid, 
base, and peroxide stress conditions, Hydrochlorothiazide labile to 
Heat and Humidity degradation. The results of forced degradation 
study were depicted in (table 2) and chromatograms in (fig. 1). The 
forced degradation study found that no interference found from 
blank and placebo at retention times of the main peak and 
impurities. All peaks found homogeneous and the peak purity data 
found within the acceptance limit. 
Precision 
The result of precision and intermediate precision was depicted in 
(table 3). The % relative standard deviation for each impurity in six 
determinations for precision and intermediate precision found 
below 2.0% confirms the preciseness of the method.  
Limit of detection and quantification 
The results for LOD and LOQ values were depicted in (table 3). The 
precision at LOQ level with six preparations found less than 5.0%. 
Linearity 
The linearity was evaluated from LOQ to 0.4% with respect to a target 
concentration of Olmesartan Medoximil 1.6 mg/ml and Hydrochloro-
thiazide 0.5 mg/ml. The results for linearity like slope, intercept and 
correlation coefficient depicted in (table 3). The correlation coefficient 
for impurities found more than 0.99. There was an excellent 
correlation between the peak area response and the concentration. 
 
Table 1: Chromatographic performance data 
Compound Retention time (min) Tailing factor Theoretical plates %RSD* 
Hydrochlorothiazide 10.8 1.04 27643 1.43 
Olmesartan Medoximil 30.7 1.03 161320 0.83 
*Six determinations of standard solution 
 
Table 2: Forced degradation data 
Conditions %Degradation Purity angle for 
Olme 
Purity threshold  
for olme 
Purity angle for 
hctz 





0.4 0.519 1.062 0.372 1.029 No 
Acid Stress 14.9 0.527 1.059 0.362 1.032 No 
Base Stress 12.4 0.528 1.051 0.359 1.027 No 
Peroxide Stress 9.9 0.531 1.060 0.364 1.033 No 
Heat Stress 3.6 0.536 1.058 0.363 1.030 No 
Humidity Stress 4.6 0.545 1.066 0.384 1.012 No 
 Olme: Olmesartan Medoximil, Hctz: Hydrochlorothiazide 
 
Table 3: Linearity, LOD, LOQ and precision data 
 Hydrochlorothiazide impurities Olmesartan medoximil impurities 
Parameter Imp-B Chlorothiazide Imp-C Acid Ester Dehydro Imp-IV Imp-III 
LOD (%) 0.005 0.011 0.005 0.006 0.014 0.007 0.007 0.010 
LOQ (%) 0.016 0.032 0.014 0.019 0.042 0.020 0.020 0.029 
Slope (b) 81680.9 82523.8 35115.5 39650.6 30458.5 27942.9 17889.5 17047.0 
 Intercept(a) -3043.9 -1220.8 1073.5 267.4 1172.6 -194.4 -829.9 -2280.3 
Corr. Coeff. 0.9988 0.9999 0.9993 0.9993 0.9996 0.9991 0.9997 0.9996 
% Y Intercept @100% Level -3.61 -1.41 2.75 0.21 1.13 -0.24 -1.49 -4.36 
Precision (% RSD)# 0.99 1.36 1.85 1.28 0.98 0.40 0.85 1.43 
Intermediate precision (% RSD)# 0.50 1.47 1.49 0.82 1.05 1.10 1.15 1.17 
Precision at LOQ (% RSD)# 0.71 3.65 1.30 2.65 2.47 1.08 1.53 1.82 
# Average %RSD for six determinations. 
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Fig. 1: Typical chromatograms of impurity spik sample (A), Acid stress sample (B), Base stress sample (C) and peroxide stress sample (D) 
 
Table 4: Accuracy data 
 Hydrochlorothiazide impurities Olmesartan medoximil impurities 

















































€ Amount spiked with respect to test the concentration of Olmesartan Medoximil (1.6 mg/ml) and Hydrochlorothiazide (0.5 mg/ml)., $ 
mean±%RSD for three determinations. 
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Table 5: Robustness data 
Compound↓/Variations→ As such Flow 0.8R  Flow 1.2R Temp 25R Temp 35R pH 3.0R pH 3.4R 
HCTZ_Imp-B NA NA NA NA NA NA NA 
HCTZ_Chlorothiazide 3.9 3.9 4.0 4.1 3. 3.9 4.0 
HCTZ 4.3 4.5 4.2 4.4 4.2 4.4 4.4 
OLME_Acid 33.4 30.4 35.6 29.9 37.2 33.2 32.6 
HCTZ_Imp-C 11.6 11.8 10.2 12.8 8.2 11.3 11.6 
OLME_Ester 26.5 25.6 26.8 19.8 32.9 23.1 22.9 
OLME 6.7 6.5 6.7 7.2 6.0 7.1 4.8 
OLME_Dehdro 14.7 15.0 14.7 14.9 14.3 15.1 15.1 
OLME_Imp-IV 28.0 27.2 29.9 28.5 26.5 30.7 25.2 
OLME_Imp-III 26.88 27.16 27.4 26.43 27.34 22.19 20.2 
HCTZ-Hydrochlorothiazide, OLME-Olmesartan Medoximil, R-Resolution between two adjacent peaks. 
 
Accuracy 
The accuracy was evaluated in triplicate by spiking respective impurities 
in the sample at 50%, 100% and 200% with respect to an analyte 
concentration of Olmesartan Medoximil 1.6 mg/ml and Hydrochloro-
thiazide 0.5 mg/ml. The % RSD result for all impurities was depicted in 
(table 4). The percent recovery found varied from 98.0% to 105.0% and 
the % RSD for three determinations found below 3.0%. 
Robustness 
With all deliberate variations of method parameters (flow, pH and 
temperature), the resolution between all the adjacent peaks found 
more than 2.0. The results for robustness study depicted in (table 5). 
Solution stability 
The similarity factor for freshly prepared standard and solution 
after 24 Hr found between 0.95 to 1.05 was as for Olmesartan 
Medoximil acid impurity up to 3Hr solution less than 0.95. Hence, 
the standard solution found a stable for 24 Hr and sample solution 
found stable for less than 3 Hr. 
CONCLUSION 
A specific, precise, accurate, linear and robust RP-HPLC method 
developed for simultaneous estimation of related substances from a 
combination of Olmesartan Medoximil and Hydrochlorothiazide in 
pharmaceutical tablet dosage form. The method was stability-indicating 
and can be used for routine analysis of production samples. 
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